Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DoorDash Inc (DASH) vs Quest Diagnostics Inc (DGX) Price & Performance

DoorDash IncTrade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

DoorDash Inc vs Quest Diagnostics Inc — how do they compare? DoorDash Inc trades at $188.64 (market cap $81.82B), while Quest Diagnostics Inc trades at $205.37 (market cap $22.80B). The key difference: DoorDash Inc is far larger — about 3.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.

DASHDGX
Market Cap
$81.82B$22.80B
Sector
Consumer CyclicalHealth
52-Week High
$281.74$216.02
52-Week Low
$146.60$166.42
Enterprise Value
$79.58B$28.82B
Dividend Yield
1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DoorDash Inc

DoorDash (DASH) trades at $189.57, down 1.17% on the day, with a bullish technical outlook supported by moving averages and key resistance near $200. The company reported strong revenue growth to $13.72B in 2025 and achieved profitability with a net income margin of 6.81%. Recent partnerships, such as with Hungry Howie's and Urban Outfitters, highlight ongoing expansion in digital commerce and loyalty programs.

The stock presents a growth opportunity with a consensus price target of $237.92, implying 25% upside, but faces risks from intense competition and high valuation multiples. Earnings momentum is mixed, with a recent beat in Q1 2026 but misses in prior quarters. Investors should weigh robust cash flow generation against elevated P/E and EV/EBITDA ratios for a balanced view.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.

DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DoorDash Inc

Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).

Read more on DASH

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX